Research programme: heat shock protein 90 inhibitors - Vernalis

Drug Profile

Research programme: heat shock protein 90 inhibitors - Vernalis

Alternative Names: CCT 018159; CCT 066950; CCT 066952; CCT 066963; CCT 066965; NVP-BEP795; NVP-BEP800; RBT 0028535; VER 49009; VER-82576/BEP800

Latest Information Update: 03 Sep 2009

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Cancer Research Technology; The Institute of Cancer Research; Vernalis
  • Developer Novartis; Vernalis
  • Class Pyrazoles
  • Mechanism of Action HSP90 heat-shock protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 20 Aug 2009 Interim pharmacodynamics data from a preclinical study in Cancer presented at the 238th American Chemical Society National Meeting (238th-ACS-2009)
  • 27 Nov 2008 Preclinical development is ongoing in Europe
  • 03 Sep 2007 A clinical candidate has been selected
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top